NCT03533127 is a Phase 3 clinical trial of LY01008 in Non Small Cell Lung Cancer, sponsored by Luye Pharma Group Ltd..

Who is sponsoring NCT03533127?

NCT03533127 is sponsored by Luye Pharma Group Ltd..

What drugs are being tested in NCT03533127?

Interventions in NCT03533127: LY01008, Bevacizumab.

What condition does NCT03533127 study?

NCT03533127 studies Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent.

Is NCT03533127 still recruiting?

NCT03533127 is currently status unknown. Last updated 10 July 2018.

Last reviewed 2018-07-10 · How we verify

NCT03533127

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

Status unknown Phase 3 Last updated 10 July 2018

What this trial tests

Phase 3 trial testing LY01008 in Non Small Cell Lung Cancer in 648 participants. Status unknown.

Timeline

27 November 2017

Primary endpoint
28 June 2020

28 December 2020

Quick facts

Lead sponsor	Luye Pharma Group Ltd.
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	648
Start date	27 November 2017
Primary completion	28 June 2020
Estimated completion	28 December 2020
Sites	1 location across China

Drugs / interventions tested

LY01008 — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Non Small Cell Lung Cancer Metastatic — all drugs for Non Small Cell Lung Cancer Metastatic →
Non Small Cell Lung Cancer Recurrent — all drugs for Non Small Cell Lung Cancer Recurrent →

Sponsor

Luye Pharma Group Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Non Small Cell Lung Cancer or Non Small Cell Lung Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Randomized, Double-blind, Multicenter Phase III Study Comparing Efficacy and Safety of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Bevacizumab Combined with Paclitaxel and Carboplatin for Treatment of Naïve Subjects with Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Tumor Microenvironment for Cancer Therapy.
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. · · 2019 · cited 865× · PMID 30781344 · DOI 10.3390/ijms20040840
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, et al · · 2020 · cited 78× · PMID 33322522 · DOI 10.3390/cancers12123729
Current treatments for non-small cell lung cancer.
Guo Q, Liu L, Chen Z, Fan Y, et al · · 2022 · cited 75× · PMID 36033435 · DOI 10.3389/fonc.2022.945102
Immunometabolism: new insights and lessons from antigen-directed cellular immune responses.
Ramalho R, Rao M, Zhang C, Agrati C, et al · · 2020 · cited 39× · PMID 32519148 · DOI 10.1007/s00281-020-00798-w
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y, Lei K, Jia Y, Ni B, et al · · 2021 · cited 20× · PMID 34184418 · DOI 10.1002/cac2.12179
Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer.
Luo X, Liu Q, Zhou Z, Yi L, et al · · 2022 · cited 18× · PMID 35517823 · DOI 10.3389/fphar.2022.832215
Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis.
Xu X, Zhang S, Xu T, Zhan M, et al · · 2022 · cited 8× · PMID 35865968 · DOI 10.3389/fphar.2022.880090
Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis.
Xiao X, Zhang G, Sun B, Wang C, et al · · 2022 · cited 6× · PMID 35836506 · DOI 10.21037/tcr-22-71

Verify or expand the search:

Other trials of LY01008

Trials testing the same drug.

NCT05110118 — Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male · Phase 1 · completed

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Luye Pharma Group Ltd. trials

Trials by the same sponsor.

NCT07516899 — Mass Balance Study of [14C] LPM3770164 in Healthy Participants · Phase 1 · not yet recruiting
NCT07391566 — LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation · Phase 1, PHASE2 · not yet recruiting
NCT07396870 — A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia · Phase 2 · not yet recruiting
NCT07371065 — To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Sub · Phase 1 · enrolling by invitation
NCT07230652 — A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03533127 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Luye Pharma Group Ltd.
Last refreshed: 10 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03533127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing